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Background: Several KCNQ1 splicing mutations have been identiﬁed in patients with type-1 long QT
syndrome (LQT1). It was suggested that the clinical severity may differ according to the aberrant splic-
ing products. There may be precipitating factors that cause cardiac events in those with a mild clinical
phenotype (forme fruste LQT1).
Methods and results:We analyzed the KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 genes in 31 consecutive
LQTS patients. A novel KCNQ1 1251+1G>A (IVS9+1G>A) mutation was identiﬁed in three probands and
their two relatives. The QT interval in all of the ﬁve individuals with mutation was not much prolonged
in the absence of precipitating factors (mean QTc was 461±30ms.). Two of the ﬁve individuals with
mutation were symptomatic. One patient (a 38-year-old female) had experienced recurrent episodes
of syncope due to ventricular tachyarrhythmias (VTAs) accompanied by QT prolongation (QTc: 750ms)
when the serum potassium concentration ([K+]) was 2.7mEq/L. After correction of [K+], the QTc interval
was shortened to 515ms, and the occurrence of VTAs ceased. Another patient (a 22-year-old female)
was resuscitated from cardio-pulmonary arrest due to VTAs. Just after resuscitation, the QTc interval was
629ms, and [K+] was 2.9mEq/L. After correction of [K+], the QTc interval was dramatically shortened
to 440ms. In order to identify abnormal splicing products of the responsible mutation, we analyzed the
reverse transcription-polymerase chain reaction products fromperipheral bloods of themutation carrier,
and identiﬁed exon 9-skipping (9) and cryptic sequential exons 8 and 9-skipping (8–9) products, as
well as a no exon-skipping product.
Conclusions: We identiﬁed a novel KCNQ splicing mutation 1251+1G>A in forme fruste LQT1, which
induces cryptic splicing. Two of the ﬁve individuals with mutation experienced VTAs in the setting of
hypokalemia, emphasizing the need to increase awareness of the signiﬁcance of hypokalemia in this
s.
3 Japsubgroup of LQT1 patient
© 201
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Long QT syndrome (LQTS) is an inherited disorder associated
ith syncope and sudden cardiac death due to ventricular tach-
arrhythmias (VTAs). More than 10 responsible genes for LQTS
ave been identiﬁed [1,2], and type-1 LQTS (LQT1), whose respon-
ible gene is KCNQ1 which encodes a major subunit of the slow
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unma 371-8511, Japan. Tel.: +81 27 220 8145; fax: +81 27 220 8158.
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component of delayed rectiﬁer potassium currents (IKs) in the
heart, is involved in approximately half of genetically affected LQTS
patients [2].
Several hundred KCNQ1 mutations, including several splicing
mutations, have been identiﬁed [3–8]. The clinical severity of LQT1
patients with KCNQ1 missense mutations depends on the muta-
tion sites. It has also been suggested that the cardiac event risk
differs depending on the aberrant splicing products of the KCNQ1
gene [6,8]. However, the difference in the triggers for cardiac events
among KCNQ1 mutations remains to be investigated.By a comprehensive genetic analysis of major LQTS-causing
genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) in 31 con-
secutive LQTS probands referred to our hospital, we identiﬁed a
novel KCNQ11251+1G>A (IVS9+1G>A)mutation in threeprobands,
vier Ltd. All rights reserved.
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KCNQ1
while swimming at the age of 10, but no family history of sudden
death. Just after fainting, cardio-pulmonary resuscitation was per-
formed on her by her family. After the arrival of the emergency
services personnel, she was deﬁbrillated by an automated external
Table 1
Clinical characteristics of a KCNQ1 1251+1G>A mutation carriers.
Genome no. Gender Age QTc w/o PF
(ms)
Symptom Possible PF
QT17 (Pro) Female 38 515 Sy Hypokalemia
QT30 (Fa) Female 14 454 Free
QT42 (Pro) Female 22 440 CPA Hypokalemia22 M. Imai et al. / Journal of
uggesting that this mutation may be relatively prevalent in our
opulation. Here, we investigated the clinical characteristics of
his splicing mutation, and tried to identify the abnormal splicing
roducts.
aterials and methods
ubjects
Thirty-one LQTS probands who were referred to Gunma
niversityHospitalwere analyzed formutations in themajor LQTS-
ausing genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2). Family
embers of mutation carriers were also included in the analysis.
enetic analysis
After obtaining appropriate approval from the institutional
eview board and written informed consent from the subjects,
enomic DNA was extracted from peripheral blood lymphocytes
sing the standard protocol of the QIAamp DNA Blood Midi Kit
QIAGEN, Hilden, Germany). All coding exons of KCNQ1, KCNH2,
CN5A, KCNE1, and KCNE2 and their splice sites were ampliﬁed
y polymerase chain reaction (PCR) using primers ﬂanking the
ntronic sequences as reportedpreviously [9–11]. The exonnumber
f KCNQ1 corresponds to that reported by Splawski et al. [9]. The
CR products were puriﬁed using the QIAquick PCR Puriﬁcation Kit
QIAGEN) and directly sequenced using an ABI PRISM 3130 Genetic
nalyzer (Applied Biosystems, Foster City, CA, USA). The mutation
as analyzed two times by independent PCR ampliﬁcation and
equencing reactions.
T-PCR
Total RNA was extracted from peripheral blood using the
tandard protocol of the QIAamp RNA Blood Mini Kit (QIAGEN).
everse transcription (RT) was performed using an AMV Reverse
ranscriptase XL for RT-PCR Kit (Takara, Otsu, Shiga, Japan), and
ubsequent PCR reactions were performed using the following
rimers. F1 primer (5′-AGGAGCTGATAACCACCCTGT-3′) and the
everse primers, R1 primer (5′-CATGCGTCGAATGACCTTAAT-3′)
nd R2 primer (5′-AGGAGTCACCCCATTGTCTTT-3′). Equal amounts
f RT-PCR products (from QT30 and control) were loaded into 2%
garose gels with Tris–acetate–EDTA buffer and electrophoresed.
hen, each band was puriﬁed using the QIAquick Gel Extraction Kit
QIAGEN) and was directly sequenced.
esults
dentiﬁcation of a novel splicing mutation in KCNQ1
We identiﬁed 12 different (ﬁve KCNQ1, ﬁve KCNH2, one SCN5A,
nd one KCNJ2), mutations among the 31 LQTS probands, including
hree probands with a novel KCNQ1 1251+1G>A mutation, which
as not identiﬁed in our 200 control alleles (Fig. 1). This suggests
hat the KCNQ1 1251+1G>A mutation is relatively prevalent in our
opulation.Wealso identiﬁed the samemutation in tworelativesof
hese probands. The individuals with mutation were one male and
our females,whosemean agewas 26±14 years (13–43 years). The
ean QTc interval without precipitating factors was 461±30ms.
he clinical characteristics of the individuals with mutation are
isted in Table 1.Fig. 1. Direct sequencing of KCNQ1 gene of Case 1. Nucleotide substitution is
indicated below.
Phenotypic characterization
Case 1
The ﬁrst proband (QT17) was a 38-year-old female who was
referred to us due to recurrent episodes of syncope. She had been
diagnosed with borderline personality disorder, alcoholism, and
iron-deﬁciency anemia, but had not been prescribed any drugs. She
had no family history of sudden death. The 12-lead electrocardio-
gram (ECG) in the emergency room showed repeated polymorphic
VTAs with QT prolongation (QTc: 750ms) (Fig. 2A and B). A blood
test showed hypokalemia (serum potassium: 2.7mEq/L), with-
out hypocalcemia (serum corrected calcium: 9.1mg/dL), and iron
deﬁciency anemia (hemoglobin: 6.0 g/dL). After an injection of
magnesium sulfate (2 g) and correction of the serum potassium
level, the occurrence of polymorphic VTAs ceased and the QT inter-
valwas shortened (QTc: 515ms) (Fig. 2C). Her daughter (QT30) also
carried the same mutation, but had been asymptomatic (Fig. 2D).
Her 12-lead ECG showed slight prolongation of the QT interval
(QTc: 451ms). However, the epinephrine provocation test, using
the Shimizu protocol [12], markedly prolonged the QT interval
(QTc: 667ms), compatible with LQT1 (Fig. 2E).
Case 2
The second proband (QT42) was a 22-year-old female who
fainted suddenlywhile brushingher teeth. Shehadbeenonadiet to
loseweight for several days. She had a history of nonfatal drowningQT40 (Pro) Male 13 451 Free
FQ17 (Fa) Female 43 442 Free
Pro, proband; Fa, family member of proband; PF, precipitating factor; Sy, syncope;
CPA, cardio-pulmonary-arrest.
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(ig. 2. 12-Lead electrocardiograms (ECGs) of Case 1 recorded at emergency room
2-Lead ECGs of a daughter (QT30) of Case 1 recorded before (left panel) and after (
eﬁbrillator, and was taken to our hospital. On arrival, her 12-lead
CG showed sinus tachycardia with marked prolongation of the QT
nterval (QTc: 629ms) (Fig. 3A). A blood test showed hypokalemia
serum potassium: 2.9mEq/L), without hypocalcemia (serum cor-
ected calcium: 8.8mg/dL). The heart rate had gradually decreased,
nd the QT interval assessed 30min later was still prolonged (QTc:
34ms) (Fig. 3B). However, after correction of the serumpotassium
evel, the QT interval was dramatically shortened (QTc: 440ms)
Fig. 3C).
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Fig. 3. 12-Lead electrocardiograms (ECGs) of Case 2 recorded at emergter arrival (A), 90min later (B), and 12 days later (C). (D) A pedigree of Case 1. (E)
panel) epinephrine provocation test.
Case 3
The third proband (QT40) was a 13-year-old male who was
referred to us because he was found to have QT prolongation at
a school physical examination. He was previously found to have
QT prolongation when he was six years old, but had been asymp-
tomatic. He had no family history of sudden death. The 12-lead
ECG showed that the QT interval was slightly prolonged (QTc:
451ms), but the epinephrine provocation test, using the Shimizu
protocol [12], markedly prolonged the QT interval (QTc: 573ms),
Day 4ater
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C
ency room just after arrival (A), 30min later, and 4 days later (C).
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he same as Fig. 2D. (D) 12-Lead ECG of a mother (FQ17) of Case 3.
ompatible with LQT1 (Fig. 4A and B). His mother (FQ17) also car-
ied the same mutation, and had slight prolongation of the QT
nterval (QTc: 454ms), but had been asymptomatic (Fig. 4C and
).
dentiﬁcation of abnormal splicing products
The human 5′ splice-site consensus sequence is MAG/GTRAGT
M is A or C; R is A or G) [8,13]. Since “G” at the position of KCNQ1
251+1 is a consensus sequence of splice-site, a mutation may
nduce abnormal splicing.
In order to identify the abnormal splicing products in the indi-
iduals with mutation, we analyzed the peripheral blood mRNA,
ecause their heart tissues were not available, and KCNQ1 mRNA
s expressed in peripheral blood lymphocytes [6,8]. We ﬁrst per-
ormed RT-PCR from the peripheral blood of the individual with
utation (QT30) and without mutation (control) using primers
panning exons 6 through 12 (Fig. 5A). Electrophoresis of the RT-
CR products from QT30 showed two shorter bands, as well as
normal-sized wild-type band (Fig. 5B, upper panel). The esti-
ated sizes of the two lower bands suggested a low possibility
f skipping exons 10 and/or 11. Therefore, to separate the bands
ore clearly, we performed RT-PCR again using primers span-
ing exons 6 through 10 (Fig. 5A and B, lower panel). The direct
equencing of these shorter bands revealed the induction of exon
-skipping (9) and sequential exons 8 and 9-skipping (8–9)nephrine provocation test. (C) A pedigree of Case 3. Symbols and abbreviations are
products (Figs. 5C and 6). Electrophoresis of the RT-PCR products
from the control showed a short-sized band (Fig. 5B), which was
compatible with the exon 8-skipping (8) product that exists in
the control as reported previously [8].
Discussion
Among 31 consecutive LQTS probands, we identiﬁed a novel
KCNQ11251+1G>Amutation,which appears to be relatively preva-
lent in our population. The mean QTc interval of the individuals
with mutation (three probands and two relatives) without pre-
cipitating factors was not much prolonged (461ms), suggesting
that they may have forme fruste LQT1. Because two of the ﬁve
individuals with mutation had experienced VTAs in the setting
of hypokalemia, it is intriguing to speculate that hypokalemia
increases cardiac risk particularly in this subgroupof LQT1patients.
However, since we did not measure the serum magnesium concen-
tration just after the occurrence of VTAs in both patients, we could
not exclude a possibility that there might be hypomagnesemia in
both patients, which also contributes to the occurrence of VTAs.
Hypokalemia is a well-known precipitating factor for exac-
erbating LQTS [14]. Sakaguchi et al. reported that hypokalemia
was associated with cardiac episodes, especially in elderly LQT1
patients, among Japanese LQTS patients [15]. However, the under-
lying mechanism causing the hypokalemia-induced exacerbation
of LQT1 has not been fully elucidated.
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eripheral blood. Sequences of each primer are listed in section ‘Materials and Met
rimers (upper panel) and that using F and R2 primers (lower panel). (C) Direct seq
The delayed rectiﬁer potassium current (IK) is a major repo-
arizing current of the cardiac action potential, and a reduction
f the IK prolongs the action potential, thus prolonging the
T interval. KCNQ1 and KCNH2 encode major subunits of the
low component (IKs) and rapid component (IKr) of IK, respec-
ively [16–18]. Hypokalemia is thought to decrease the IKr/KCNH2
urrents because of its enhanced inactivation and increased inter-
alization and degradation of KCNH2 channels in the plasma
embrane [19,20], and thus prolongs the QT interval. Although
Ks has been thought to be much less sensitive to the serum
otassium level, a recent study demonstrated that KCNH2 and
CNQ1 physically associated at the plasma membrane, and that
ypokalemia-induced KCNH2 endocytic degradation leads to the
ransport of KCNQ1 into the cell for degradation [21]. Interestingly,
he VTAs of Case 1 occurred not during bradycardia but tachycar-
ia, possibly due, in part, to anemia. An increased heart rate, which
s known as an aggravating factor for LQT1, might also contribute
o the occurrence of the VTAs in Case 1. This suggests that the
utant IKs/KCNQ1 current might also be reduced in the setting of
ypokalemia. Further studies are warranted to determine whether
ot only the IKr/KCNH2 current but also the IKs/KCNQ1 current is
educed by hypokalemia in the mutation carriers.In both Case 1 and Case 2, the hypokalemia might have been
nduced by an unbalanced diet. Therefore, it would be possible to
revent the occurrence of VTAs if patients were properly educated
Topology of KCNQ1
S1 S2 S3 S4 S5 S6
exon 8 exon 9
c.1251
ig. 6. Topology of KCNQ1 representing exons 8 and 9 which are skipped by the
CNQ1 1251+1G>A mutation.rrier. (A) Schematic representation of the location of primers used in RT-PCR from
. (B) Electrophoresis of the RT-PCR products from QT30 and control using F and R1
ng of upper (U), middle (M), and lower (L) bands of the gel (lower panel of B).
about the risk of the induction of hypokalemia by an unbalanced
diet, which emphasizes the importance of patient education.
We identiﬁed exon-skipping products (9 and 8–9) of KCNQ1
from a KCNQ1 1251+1G>A (IVS9+1G>A) mutation carrier. Tsuji-
Wakisaka et al. reported that KCNQ1 IVS7+3A>G and c.1032G>A
produced exon 7-skipping and sequential exons 7 and 8-skipping
products (7 and 7–8) [8]. Therefore, we expected that the
mutant might produce exon 9-skipping (9) and exons 9 and 10-
skipping (9–10) products. However, contrary to our expectation,
in addition to 9 which was expected to be produced, the mutant
cryptically produced sequential skipping of exons 8 and 9 (8–9).
Since the exon 8-skipping product (8) exists even in controls as
reported by Tsuji-Wakisaka et al. [8], the production of 8–9 could
be a clue to elucidate the mechanism(s) underlying the abnormal
splicing.
Although the individuals having the KCNQ1 1251+1G>A muta-
tion may present with mild QT prolongation in the absence of
precipitating factors, quantitative and functional assessments of
abnormal splicing products, and further investigation of the fam-
ily members of the mutation carriers are required to conclude that
all of the mutation carriers indeed present with a mild phenotype
without precipitating factors.
In conclusion, we identiﬁed a novel KCNQ1 splicing mutation,
1251+1G>A, in patients with forme fruste LQT1, which induces
cryptic splicing of KCNQ1. Our data emphasize the critical impor-
tance of hypokalemia as a potential trigger of lethal arrhythmias in
a subset of LQT1 patients with a mild clinical phenotype.
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